ADMP DOES have a failing product line. Giving away insulin won't do much to your stock price especially after the revenue split. Zimhi will not be adopted by the majority of groups using the nasal application. They are smart and realize the 1 TINY advantage of 'time to administer' won't be utilized to justify all the things that would come with changing over.
The President of the United States was given what the 'best' doctors felt was the 'best' treatment available and it wasn't Tempol. Again, Tempol supposedly has decades of safety data and they said NO to it. That is a clear sign Tempol results are NOT there. Yes, the Presidents doctor WOULD have access to the data on Tempol. Trust me on that. Based on this I am very concerned that my shares are crap. Time will tell.
But lets see what the markets and the insiders think of ADMP...still not buying @ .38/share. But, but, but...
Market Data 
Markets 
AI
